Alterola Biotech Inc. Registration Statement Declared Effective

Rhea-AI Summary

Alterola Biotech Inc. (OTC PINK:ABTI) announced that its Registration Statement on Form S-1 was declared effective by the SEC on October 19, 2021. The company plans to use the net proceeds from the Offering to enhance its research, clinical development programs, and general corporate purposes. Terms of the Offering will be finalized at market pricing. The Prospectus with details on the Offering is available on EDGAR. Investors are urged to review it before making investment decisions. This release does not constitute an offer of any securities.

Positive

• SEC has declared the Registration Statement effective.
• Proceeds from the Offering will advance research and clinical programs.

Negative

• No assurance on the completion, size, or terms of the Offering.
• Forward-looking statements contain risks and uncertainties related to product development and regulatory processes.

BIRKENHEAD, UK / ACCESSWIRE / November 12, 2021 / Alterola Biotech Inc. ("Alterola Biotech" or the "Company") (OTC PINK:ABTI) a clinical-stage biotechnology company focused on developing cannabinoid therapies for the treatment of diseases, having filed its Registration Statement on Form S-1 with the Securities and Exchange Commission on the 19th of October 2021, has been informed that the Registration Statement has been declared effective.

The Company intends to use the net proceeds from the Offering to advance the Company's research and clinical development programs, additional product development, and for general corporate purposes.

Following its Common Stock Purchase Agreement with EMC2 on August 11, 2021 the Offering is expected to be priced in the context of the market, with the final terms of the Offering to be determined at the time of pricing. There can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.

The Prospectus contains important detailed information about the Offering and is located on EDGAR at www.sec.gov. Prospective investors should read the Prospectus before making an investment decision.

This press release does not constitute an offer of any securities for sale.

About Alterola Biotech Inc.
Alterola is a UK based pharmaceutical company developing cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs). pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs and targeting European novel food approval of cannabinoid-based, cannabinoid-like and non-cannabinoid ingredients and products. In addition, the company is seeking to develop such bulk ingredients for supply into the cosmetic sector. If you would like more information about Alterola Biotech Inc., please visit our website https://alterola-abti.com/ or contact our Investor Relations Department at +353 86 838 9812 or ir@alterolabio.com.

Notice Regarding Forward Looking Statements
This news release contains forward-looking statements that reflect ALTEROLA's current expectations regarding future events, including statements regarding financial performance, the timing of preclinical studies and clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the relevance of ALTEROLA product candidates currently in development. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of ALTEROLA's research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, and the potential acceptance of any future product that may (if ever) be approved by the appropriate regulatory authorities by consumer and medical professionals. A further list and description of risks and uncertainties associated with an investment in ALTEROLA can be found in ALTEROLA's filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. ALTEROLA undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

SOURCE: Alterola Biotech, Inc.

View source version on accesswire.com:
https://www.accesswire.com/672631/Alterola-Biotech-Inc-Registration-Statement-Declared-Effective

FAQ

What was declared effective for Alterola Biotech on October 19, 2021?

The Registration Statement on Form S-1 was declared effective by the SEC.

What will Alterola Biotech do with the proceeds from the Offering?

The proceeds will be used to advance research, clinical development programs, and for general corporate purposes.

Are there any guarantees regarding the Offering's completion or terms?

No, the company cannot assure when the Offering may be completed or its actual size or terms.

Where can I find detailed information about Alterola Biotech's Offering?

The detailed Prospectus is located on EDGAR at www.sec.gov.